MIRM

Mirum Pharmaceuticals, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1759425Held by 7 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$521.0M

Net Income FY2025

$(23.0M)

EPS (Basic, as reported)

$-0.47

Net Margin FY2025

-4.5%

ROE FY2025

-7.4%

Total Equity

$315.0M

Shares Out

65M

Business description

Mirum Pharmaceuticals, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2018–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 0 → 521

Fiscal yearFY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue——01977186337521

Selling, general & administrative———(59)(89)(146)(202)(257)

General & administrative—(12)(23)(59)————

Total operating expenses—(55)(104)(193)(208)(296)(424)(543)

Operating income—(55)(104)(173)(131)(109)(88)(22)

Interest expense————(16)(15)(14)(14)

Interest & investment income—2204141413

Other income (expense), net—00(1)0(3)12

Pre-tax income—(53)(103)(84)(142)(162)(87)(21)

Income tax expense—000(6)(1)(1)(2)

Net income—(53)(103)(84)(136)(163)(88)(23)

EPS — basic———($2.77)($4.01)($4.00)($1.85)($0.47)

EPS — diluted———($2.77)($4.02)($4.00)($1.85)($0.47)

Shares outstanding — basic (M)———3034414850

Shares outstanding — diluted (M)———3034414850

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.